Table 3 Treatments for HAE available in Canada that are supported by a high level of evidence [7, 16]
From: Angioedema
HAE-specific treatment | Product name | Mechanism of action | Approved indications in Canada | Dose and route of administration | Age indications |
|---|---|---|---|---|---|
Plasma-derived C1-INH† | Berinert | Replaces C1-INH | Acute treatment | 20 U/kg intravenous as needed | Pediatric and adult |
Cinryze | Replaces C1-INH | Long-term prophylaxis | 1000 U intravenous q 3–4 days | ≥ 12 years | |
Haegarda | Replaces C1-INH | Long-term prophylaxis | 60 U/kg body weight twice weekly subcutaneously (every 3–4 days) | ≥ 12 years | |
Icatibant | Firazyr | Synthetic selective and specific antagonist of bradykinin 2 receptor | Acute treatment | 30 mg subcutaneous injection as needed; dose-adjusted for adolescents < 65 kg and children ≥ 2 years* | ≥ 2 years |
Lanadelumab | Takhzyro | Fully human monoclonal antibody that binds plasma kallikrein and inhibits its proteolytic activity | Long-term prophylaxis | 300 mg subcutaneous injection every 2 weeks A dosing interval of 300 mg every 4 weeks may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months | ≥ 12 years |
Berotralstat | Orladeyo | Oral, selective inhibitor of plasma kallikrein that blocks enzymatic activity of plasma kallikrein in releasing bradykinin | Long-term prophylaxis | 150 mg daily taken orally with food | ≥ 12 years |